ImexpharmSTC:IMP -1.38%98 Gross Margin % is 41.48% as of Mar. 2026, which is 4% above its 10-year median of 39.80. GuruFocus rates STC:IMP with a GF Score™ of 98/100 and a GF Value™ of ₫51,706.57 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 938 Drug Manufacturers companies, Imexpharm ranks worse than 62.05% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Imexpharm's Gross Profit for the
three
months ended in Mar. 2026 was ₫226,583 Mil. Imexpharm's Revenue for the
three
months ended in Mar. 2026 was ₫546,206 Mil. Therefore, Imexpharm's Gross Margin % for the quarter that ended in Mar. 2026 was 41.48%.
The historical rank and industry rank for Imexpharm's Gross Margin % or its related term are showing as below:
STC:IMP'
s Gross Margin % Range Over the Past 10 Years
Min: 37.48 Med: 39.8 Max: 42.43
Current: 41.52
During the past 13 years, the highestGross Margin % of Imexpharm was 42.43%. The lowest was 37.48%. And the median was 39.80%.
STC:IMP's Gross Margin % is ranked worse than 62.05% of 938
companies
in the Drug Manufacturers industry
Industry Median: 48.44
vs STC:IMP: 41.52
Imexpharm had a gross margin of 41.48% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Imexpharm was 0.30% per year.
Imexpharm (STC:IMP) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Imexpharm had a gross margin of 41.48% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Imexpharm Gross Margin % Related Terms
Imexpharm Gross Margin % Historical Data
* Premium members only.
The historical data trend for Imexpharm's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Imexpharm's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imexpharm Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Imexpharm's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Imexpharm's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Imexpharm (STC:IMP) has a Gross Margin % of 41.48% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Imexpharm and its competitors. This is near median its historical median of 39.80. Over the past decade, Imexpharm's Gross Margin % has ranged from 37.48 to 42.43. According to the industry distribution chart, Imexpharm ranks #582 out of 938 companies in the Drug Manufacturers industry, placing it in the top 62%.
Is Imexpharm's Gross Margin % too high?
Imexpharm's current Gross Margin % of 41.48% is near median its 10-year median of 39.80. Over the past 10 years, this metric has ranged from a low of 37.48 to a high of 42.43. The Drug Manufacturers industry median Gross Margin % is 48.44. Imexpharm's value of 41.48% is 14.4% below this industry median. Based on the distribution chart, Imexpharm ranks #582 out of 938 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Imexpharm has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Imexpharm's Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Imexpharm ranks #582 out of 938 companies for Gross Margin %. This places Imexpharm in the lower half of its industry. The industry median Gross Margin % is 48.44. Imexpharm's value of 41.48% is 14.4% below this benchmark. Historically, Imexpharm's own Gross Margin % has ranged from 37.48 to 42.43 over the past decade. While the company's 10-year median is 39.80 vs. the industry median of 48.44, Imexpharm has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.44, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Imexpharm's current Gross Margin % of 41.48% is 14.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Imexpharm and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imexpharm's current Gross Margin % is 41.48%, which is near median its own 10-year median of 39.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imexpharm stock overvalued right now?
Based on GuruFocus' analysis, Imexpharm (STC:IMP) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫51,706.57, compared to a current price of ₫42,900.00 — trading 17% below its estimated fair value. The current Gross Margin % is 41.48%, which is near median its 10-year median of 39.80 and 14.4% below the Drug Manufacturers industry median of 48.44. Imexpharm's overall GF Score™ is 98/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Imexpharm (STC:IMP), the current Gross Margin % is 41.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Imexpharm (STC:IMP) Overvalued in 2026?
Based on GuruFocus' analysis, Imexpharm stock appears to be undervalued.
The current stock price of ₫42,900.00 is trading 17% below its estimated GF Value™ of ₫51,706.57.
GuruFocus considers Imexpharm to be Modestly Undervalued.
Key valuation signals for STC:IMP:
Gross Margin %: 41.48% (near median its 10-year median of 39.80)
GF Value™: ₫51,706.57 vs. price of ₫42,900.00 (17% below fair value)
Industry Position: 14.4% below the Drug Manufacturers median (#582 of 938)
No single metric tells the full story. See the STC:IMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Imexpharm Corp is engaged in the manufacture, import, export, and trade of pharmaceuticals and medicinal chemical products. The company's products include oral and injective antibiotic, digestion, central nervous system, cardiovascular, diabetes, musculoskeletal system, respiratory system, analgesic-anti-inflammatory, anti-allergy, ophthalmology, external drugs, and anti-parasitic, as well as vitamins and minerals.
98GF Score
Get the complete analysis for STC:IMP
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:IMP has been successfully added to your 
